Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 May;40(5):1304–1307. doi: 10.1128/aac.40.5.1304

Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors.

J C Hastings 1, H Selnick 1, B Wolanski 1, J E Tomassini 1
PMCID: PMC163316  PMID: 8723491

Abstract

We previously identified a series of compounds which specifically inhibited the transcription of influenza A and B viruses (J. Tomassini, H. Selnick, M.E. Davies, M.E. Armstrong, J. Baldwin, M. Bourgeois, J. Hastings, D. Hazuda, J. Lewis, W. McClements, G. Ponticello, E. Radzilowski, G. Smith, A. Tebben, and A. Wolfe, Antimicrob. Agents Chemother. 38:2827-2837, 1994). The compounds, 4-substituted 2,4-dioxobutanoic acids, selectively targeted the cap-dependent endonuclease activity of the transcriptase complex. Additionally, several of these compounds effectively inhibited the replication of influenza virus but not other viruses in cell culture assays. Here, we report on the anti-influenza virus activities of other potent derivatives of the series evaluated in both in vitro and in vivo infectivity assays. These compounds inhibited the replication of influenza virus in yield reduction assays, with 50% inhibitory concentrations ranging from 0.18 to 0.71 microM. These 50% inhibitory concentrations were similar to those observed for inhibition of in vitro transcription (0.32 to 0.54 microM). One selected compound also elicited a dose-dependent inhibition of influenza virus replication in mice following an upper respiratory tract challenge. These studies demonstrate the antiviral efficacy of this inhibitor class and thereby establish the utility of influenza virus endonuclease as a chemotherapeutic target.

Full Text

The Full Text of this article is available as a PDF (194.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Braam J., Ulmanen I., Krug R. M. Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell. 1983 Sep;34(2):609–618. doi: 10.1016/0092-8674(83)90393-8. [DOI] [PubMed] [Google Scholar]
  2. Jin H., Elliott R. M. Characterization of Bunyamwera virus S RNA that is transcribed and replicated by the L protein expressed from recombinant vaccinia virus. J Virol. 1993 Mar;67(3):1396–1404. doi: 10.1128/jvi.67.3.1396-1404.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Nichol S. T., Penn C. R., Mahy B. W. Evidence for the involvement of influenza A (fowl plague Rostock) virus protein P2 in ApG and mRNA primed in vitro RNA synthesis. J Gen Virol. 1981 Dec;57(Pt 2):407–413. doi: 10.1099/0022-1317-57-2-407. [DOI] [PubMed] [Google Scholar]
  4. Novak M., Moldoveanu Z., Schafer D. P., Mestecky J., Compans R. W. Murine model for evaluation of protective immunity to influenza virus. Vaccine. 1993;11(1):55–60. doi: 10.1016/0264-410x(93)90339-y. [DOI] [PubMed] [Google Scholar]
  5. Palese P., Ritchey M. B., Schulman J. L. P1 and P3 proteins of influenza virus are required for complementary RNA synthesis. J Virol. 1977 Mar;21(3):1187–1195. doi: 10.1128/jvi.21.3.1187-1195.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Patterson J. L., Holloway B., Kolakofsky D. La Crosse virions contain a primer-stimulated RNA polymerase and a methylated cap-dependent endonuclease. J Virol. 1984 Oct;52(1):215–222. doi: 10.1128/jvi.52.1.215-222.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Plotch S. J., Bouloy M., Ulmanen I., Krug R. M. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell. 1981 Mar;23(3):847–858. doi: 10.1016/0092-8674(81)90449-9. [DOI] [PubMed] [Google Scholar]
  8. Renegar K. B. Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci. 1992 Jun;42(3):222–232. [PubMed] [Google Scholar]
  9. Rossier C., Patterson J., Kolakofsky D. La Crosse virus small genome mRNA is made in the cytoplasm. J Virol. 1986 May;58(2):647–650. doi: 10.1128/jvi.58.2.647-650.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ryan D. M., Ticehurst J., Dempsey M. H., Penn C. R. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother. 1994 Oct;38(10):2270–2275. doi: 10.1128/aac.38.10.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rychlik W., Domier L. L., Gardner P. R., Hellmann G. M., Rhoads R. E. Amino acid sequence of the mRNA cap-binding protein from human tissues. Proc Natl Acad Sci U S A. 1987 Feb;84(4):945–949. doi: 10.1073/pnas.84.4.945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Shi L., Summers D. F., Peng Q., Galarz J. M. Influenza A virus RNA polymerase subunit PB2 is the endonuclease which cleaves host cell mRNA and functions only as the trimeric enzyme. Virology. 1995 Apr 1;208(1):38–47. doi: 10.1006/viro.1995.1127. [DOI] [PubMed] [Google Scholar]
  13. Tomassini J., Selnick H., Davies M. E., Armstrong M. E., Baldwin J., Bourgeois M., Hastings J., Hazuda D., Lewis J., McClements W. Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrob Agents Chemother. 1994 Dec;38(12):2827–2837. doi: 10.1128/aac.38.12.2827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ulmanen I., Broni B. A., Krug R. M. Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci U S A. 1981 Dec;78(12):7355–7359. doi: 10.1073/pnas.78.12.7355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993 Mar 19;259(5102):1745–1749. doi: 10.1126/science.8456302. [DOI] [PubMed] [Google Scholar]
  16. Woods J. M., Bethell R. C., Coates J. A., Healy N., Hiscox S. A., Pearson B. A., Ryan D. M., Ticehurst J., Tilling J., Walcott S. M. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother. 1993 Jul;37(7):1473–1479. doi: 10.1128/aac.37.7.1473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Yamashita M., Krystal M., Palese P. Comparison of the three large polymerase proteins of influenza A, B, and C viruses. Virology. 1989 Aug;171(2):458–466. doi: 10.1016/0042-6822(89)90615-6. [DOI] [PubMed] [Google Scholar]
  18. Yetter R. A., Lehrer S., Ramphal R., Small P. A., Jr Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun. 1980 Aug;29(2):654–662. doi: 10.1128/iai.29.2.654-662.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. de la Luna S., Martínez C., Ortín J. Molecular cloning and sequencing of influenza virus A/Victoria/3/75 polymerase genes: sequence evolution and prediction of possible functional domains. Virus Res. 1989 Jun;13(2):143–155. doi: 10.1016/0168-1702(89)90012-9. [DOI] [PubMed] [Google Scholar]
  20. von Itzstein M., Wu W. Y., Kok G. B., Pegg M. S., Dyason J. C., Jin B., Van Phan T., Smythe M. L., White H. F., Oliver S. W. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 1993 Jun 3;363(6428):418–423. doi: 10.1038/363418a0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES